Evidence map›Paper›PMID 41614298›Full record

ArticleNucleic acids research2026

Genome-wide extraction of differentially methylated DNA regions using adapter-anchored proximity primers.

Farzaneh Darbeheshti, Hayet Radia Zeggar, Hamzeh Salmani, Yibin Liu, Eleni Thanou, Athina Markou, Giannis Vatsellas, Samira Ghazali, Ruolin Liu, Evi Lianidou and 2 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Farzaneh DarbeheshtiDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, United States.
Hayet Radia ZeggarDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, United States.
Hamzeh SalmaniDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, United States.
Yibin LiuState Key Laboratory of Metabolism and Regulation in Complex Organisms, College of Chemistry and Molecular Sciences, Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430072, China.ORCID 0000-0003-3451-0212
Eleni ThanouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens 15771,Greece.
Athina MarkouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens 15771,Greece.
Giannis VatsellasGreek Genome Center, Biomedical Research Foundation Academy of Athens, Athens 11527, Greece.
Samira GhazaliDepartment of Immunology, Harvard Medical School, Boston, MA 02215, United States.
Ruolin LiuBroad Institute of MIT and Harvard, Cambridge, MA 02142, United States.ORCID 0000-0001-9059-6335
Evi LianidouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens 15771,Greece.
Viktor A AdalsteinssonBroad Institute of MIT and Harvard, Cambridge, MA 02142, United States.ORCID 0000-0003-4555-2485
G Mike MakrigiorgosDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, United States.ORCID 0000-0001-7598-2406

Funding

Comprehensive minimal residual disease tracking in cancerR01CA221874 · NCI · DANA-FARBER CANCER INST · PI Viktor Adalsteinsson, G. Mike Makrigiorgos · 2018 to 2026
$2.5M
NCI NIH HHS R01 CA221874NIH HHS 2R01CA221874-05
6 · The paper itself

Abstract

The epigenetic deregulation of CpG islands (CGIs) plays a crucial role in cancer initiation and progression. CGIs comprise 1%-2% of the human genome and are rich in differentially methylated regions (DMRs) that can serve as biomarkers in clinical samples and liquid biopsies. Focusing epigenetic sequencing on CpG-rich regions, including CGIs, while avoiding non-informative sequences, offers an efficient and sensitive approach for cancer detection and monitoring, especially in samples with excess normal DNA. To this end, we developed adaptor-anchored methylation amplification via proximity primers (aMAPPs), a versatile PCR-based enrichment method. Proximity primers (PPs) are specially designed primers that amplify either methylated or unmethylated proximal CpGs, depending on the selected methylation conversion method. aMAPP achieves high-coverage of genome-wide CGIs and detects numerous DMRs in tumor samples compared to adjacent normal tissue using ultra-low depth sequencing (∼300 000 reads). aMAPP enables detection of aberrant methylation down to 0.01% allelic frequency in tumor DNA dilutions and cell-free DNA, requires only picogram DNA input, and can be adapted to enrich either small panels of cancer-specific DMRs or large genomic-fractions including >90% of genomic CGIs. Overall, aMAPP provides a simple, cost-effective, and highly sensitive strategy for capturing the epigenetic footprint of genome-wide CpGs and identifying aberrant methylation events.

Indexed as

DNA MethylationDNA PrimersCpG IslandsDNAEpigenesis, GeneticGenome, HumanHigh-Throughput Nucleotide SequencingHumansPolymerase Chain ReactionSequence Analysis, DNADNADNA Primers

Identifiers

PMID41614298
PMCPMC12856212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.